Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
25,669,673
-
Total 13F shares
-
23,949,691
-
Share change
-
+1,088,004
-
Total reported value
-
$364,277,074
-
Put/Call ratio
-
2.9%
-
Price per share
-
$15.21
-
Number of holders
-
107
-
Value change
-
+$11,366,358
-
Number of buys
-
52
-
Number of sells
-
42
Institutional Holders of Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) as of Q1 2025
As of 31 Mar 2025,
Tourmaline Bio, Inc. - Common stock, par value $0.0001 per share (TRML) was held by
107 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
23,949,691 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, L.P., Avoro Capital Advisors LLC, BlackRock, Inc., TCG Crossover Management, LLC, QVT Financial LP, Pfizer Inc, VANGUARD GROUP INC, Blue Owl Capital Holdings LP, Octagon Capital Advisors LP, and QIMING U.S. VENTURES MANAGEMENT, LLC.
This page lists
107
institutional shareholders reporting positions in this security
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.